Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania

Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, and the Bipolar Disorders Program, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Journal of psychiatry & neuroscience: JPN (Impact Factor: 5.86). 10/2006; 31(5):326-32.
Source: PubMed


Previous studies have suggested that oxidative stress may play a role in the pathophysiology of bipolar disorder (BD). Moreover, recent studies indicate that lithium and valproate exert neuroprotective effects against oxidative stress. We studied the effects of the mood stabilizers lithium and valproate on amphetamine-induced oxidative stress in an animal model of mania.
In the first model (reversal treatment), adult male Wistar rats received d-amphetamine or saline for 14 days, and between the 8th and 14th days, they were treated with lithium, valproate or saline. In the second model (prevention treatment), rats were pretreated with lithium, valproate or saline, and between the 8th and 14th days, they received d-amphetamine or saline. We assessed locomotor activity with the open-field task. We measured thiobarbituric acid reactive substances (TBARS) and protein carbonyl formation, as parameters of oxidative stress, and superoxide dismutase (SOD) and catalase (CAT), the major antioxidant enzymes, in the prefrontal cortex and hippocampus.
Lithium and valproate reversed (reversal treatment model) and prevented (prevention treatment model) amphetamine-induced hyperactivity and reversed and prevented amphetamine-induced TBARS formation in both experiments. However, the co-administration of lithium or valproate with amphetamine increased lipid peroxidation, depending on the brain region and treatment regimen. No changes in protein carbonyl formation were observed. SOD activity varied with different treatment regimens, and CAT activity increased when the index of lipid peroxidation was more robust.
Our findings suggest that lithium and valproate exert protective effects against amphetamine-induced oxidative stress in vivo, further supporting the hypothesis that oxidative stress may be associated with the pathophysiology of BD.

Download full-text


Available from: Fabrícia Petronilho, May 23, 2014
41 Reads
  • Source
    • "the brain of stressed mice, but the effect was not statistically significant. Lithium has been reported to ameliorate ROS levels in an animal model of mania (Frey et al., 2006 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Evidence suggests that mammalian target of rapamycin (mTOR) activation mediates ketamine's rapid but transient antidepressant effects, and that glycogen synthase kinase-3β (GSK-3β) inhibits this pathway. However, ketamine has associated psychotomimetic effects and a high risk of abuse. The mood stabilizer lithium is a GSK-3 inhibitor with strong anti-suicidal properties. Here, we used a mouse stress model to investigate whether adjunct lithium treatment would potentiate ketamine's antidepressant-like effects. Mice received chronic restraint stress and long-term pre- or post-ketamine lithium treatment in drinking water. The effects of lithium on ketamine-induced antidepressant-like effects, activation of the mTOR/brain-derived neurotrophic factor (BDNF) signaling pathways, oxidative stress, and dendritic spine density in the brain of mice were investigated. Sub-therapeutic (600 mg/L) lithium-pretreated mice exhibited an antidepressant-like response to an ineffective ketamine (2.5 mg/kg, i.p.) challenge in the forced swim test. Both the antidepressant-like effects and restoration of dendritic spine density in the medial prefrontal cortex (PFC) of stressed mice induced by a single ketamine (50 mg/kg) injection were sustained by post-ketamine treatment with 1200 mg/L of lithium for at least two weeks. These benefits of lithium treatments were associated with activation of the mTOR/BDNF signaling pathways in the PFC. Acute ketamine (50 mg/kg) injection also significantly increased lipid peroxidation, catalase activity, and oxidized glutathione levels in stressed mice. Notably, these oxidative stress markers were completely abolished by pretreatment with 1200 mg/L of lithium. Our results suggest a novel therapeutic strategy and justify the use of lithium in patients who benefit from ketamine. Published by Oxford University Press on behalf of CINP 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
    The International Journal of Neuropsychopharmacology 12/2014; 18(6). DOI:10.1093/ijnp/pyu102 · 4.01 Impact Factor
  • Source
    • "We also measured the effect of social defeatinduced stress on oxidative stress within three critical brain areas, considered vital for depression, anxiety and cognition, namely, hippocampus, amygdala and prefrontal cortex (McEwen et al., 2012). Oxidative stress which is defined as the imbalance between production of reactive oxygen and nitrogen species (RONS) and their inefficient decomposition by the antioxidant system (Lau et al., 2011; Patki et al., 2009; Sies, 1997), has been implicated in the pathophysiology of depression, anxiety and other psychiatric disorders (Frey et al., 2006; Gibson et al., 2012; Kiecolt-Glaser et al., 2013; Maurer et al., 2001; Rezin et al., 2009). Actually, large consumption of oxygen, high amount of polyunsaturated fatty acids and iron content with diminished antioxidant enzymatic activity make brain a vulnerable target for oxidative stress (Evans, 1993) increasing its vulnerability to disease. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the present study, we have examined the behavioral and biochemical effect of induction of psychological stress using a modified version of the resident-intruder model for social stress (social defeat). At the end of the social defeat protocol, body weights, food and water intake were recorded, depression and anxiety-like behaviors as well as learning-memory function was examined. Biochemical analysis including oxidative stress measurement, inflammatory markers and other molecular parameters, critical to behavioral effects were examined. We observed a significant decrease in the body weight in the socially defeated rats as compared to the controls. Furthermore, social defeat increased anxiety-like behavior and caused memory impairment in rats (P<0.05). Socially defeated rats made significantly more errors in long term memory tests (P<0.05) as compared to control rats. Furthermore, brain extracellular signal-regulated kinase-1/2 (ERK1/2), and an inflammatory marker, interleukin (IL)-6 were activated (P<0.05), while the protein levels of glyoxalase (GLO)-1, glutathione reductase (GSR)-1, calcium/calmodulin-dependent protein kinase type (CAMK)-IV, cAMP-response-element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) were significantly less (P<0.05) in the hippocampus, but not in the prefrontal cortex and amygdala of socially defeated rats, when compared to control rats. We suggest that social defeat stress alters ERK1/2, IL-6, GLO1, GSR1, CAMKIV, CREB, and BDNF levels in specific brain areas, leading to oxidative stress-induced anxiety-depression-like behaviors and as well as memory impairment in rats.
    Brain research 10/2013; 1539. DOI:10.1016/j.brainres.2013.09.033 · 2.84 Impact Factor
  • Source
    • "Treatment with lithium selectively reduced hyperactivity in LAB, but not HAB and NAB, mice, indicating that LAB mice share some pathogenetic features with manic individuals. In humans, amphetamine has been shown to increase general activity in majority of normal adults and to precipitate manic episodes in bipolar disorders (Gould et al., 2001; Frey et al., 2006) and positive symptoms in schizophrenia (Irwin et al., 1987), while exerting a paradoxical “calming effect” in ADHD patients (Greenhill, 1992). In the present study, treatment with amphetamine increased locomotor activity in HAB/NAB mice, but exerted a calming effect on locomotion in both LAB-I and LAB-S mice. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We established mouse models of extremes in trait anxiety, which are based on selective breeding for low vs. normal vs. high open-arm exploration on the elevated plus-maze. Genetically selected low anxiety-related behavior (LAB) coincided with hyperactivity in the home cage. Given the fact that several psychiatric disorders such as schizophrenia, mania, and attention deficit hyperactivity disorder (ADHD) share hyperactivity symptom, we systematically examined LAB mice with respect to unique and overlapping endophenotypes of the three diseases. To this end Venn diagrams were used as an instrument for discrimination of possible models. We arranged the endophenotypes in Venn diagrams and translated them into different behavioral tests. LAB mice showed elevated levels of locomotion in the open field (OF) test with deficits in habituation, compared to mice bred for normal (NAB) and high anxiety-related behavior (HAB). Cross-breeding of hypoactive HAB and hyperactive LAB mice resulted in offspring showing a low level of locomotion comparable to HAB mice, indicating that the HAB alleles are dominant over LAB alleles in determining the level of locomotion. In a holeboard test, LAB mice spent less time in hole exploration, as shown in patients with schizophrenia and ADHD; however, LAB mice displayed no impairments in social interaction and prepulse inhibition (PPI), implying a unlikelihood of LAB as an animal model of schizophrenia. Although LAB mice displayed hyperarousal, active coping styles, and cognitive deficits, symptoms shared by mania and ADHD, they failed to reveal the classic manic endophenotypes, such as increased hedonia and object interaction. The neuroleptic haloperidol reduced locomotor activity in all mouse lines. The mood stabilizer lithium and the psychostimulant amphetamine, in contrast, selectively reduced hyperactivity in LAB mice. Based on the behavioral and pharmacological profiles, LAB mice are suggested as a novel rodent model of ADHD-like symptoms.
    Frontiers in Behavioral Neuroscience 08/2013; 7:103. DOI:10.3389/fnbeh.2013.00103 · 3.27 Impact Factor
Show more